VERRICA PHARMACEUTICALS INC (VRCA)
US92511W1080 - Common Stock
Taking everything into account, VRCA scores 2 out of 10 in our fundamental rating. VRCA was compared to 191 industry peers in the Pharmaceuticals industry. VRCA may be in some trouble as it scores bad on both profitability and health. VRCA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year VRCA has reported negative net income.
VRCA had a negative operating cash flow in the past year.
VRCA had negative earnings in each of the past 5 years.
In the past 5 years VRCA always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -258.12%, VRCA is not doing good in the industry: 92.39% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -258.12% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-60.22%
ROA(5y)-55.89%
ROE(3y)-169.25%
ROE(5y)-136.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 74.08%, VRCA belongs to the best of the industry, outperforming 80.43% of the companies in the same industry.
VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VRCA has been increased compared to 1 year ago.
The number of shares outstanding for VRCA has been increased compared to 5 years ago.
Compared to 1 year ago, VRCA has a worse debt to assets ratio.
2.2 Solvency
VRCA has an Altman-Z score of -18.78. This is a bad value and indicates that VRCA is not financially healthy and even has some risk of bankruptcy.
VRCA has a worse Altman-Z score (-18.78) than 84.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.78 |
ROIC/WACCN/A
WACC11.45%
2.3 Liquidity
A Current Ratio of 1.34 indicates that VRCA should not have too much problems paying its short term obligations.
VRCA has a Current ratio of 1.34. This is in the lower half of the industry: VRCA underperforms 78.80% of its industry peers.
VRCA has a Quick Ratio of 1.22. This is a normal value and indicates that VRCA is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.22, VRCA is not doing good in the industry: 74.46% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.22 |
3. Growth
3.1 Past
The earnings per share for VRCA have decreased strongly by -71.03% in the last year.
Looking at the last year, VRCA shows a very strong growth in Revenue. The Revenue has grown by 186.92%.
EPS 1Y (TTM)-71.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
Revenue 1Y (TTM)186.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-161.06%
3.2 Future
VRCA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.46% yearly.
VRCA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 91.12% yearly.
EPS Next Y-11.31%
EPS Next 2Y26.1%
EPS Next 3Y20.26%
EPS Next 5Y18.46%
Revenue Next Year95.42%
Revenue Next 2Y97.59%
Revenue Next 3Y112.21%
Revenue Next 5Y91.12%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
VRCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRCA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VRCA's earnings are expected to grow with 20.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.1%
EPS Next 3Y20.26%
5. Dividend
5.1 Amount
VRCA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VERRICA PHARMACEUTICALS INC
NASDAQ:VRCA (1/3/2025, 8:09:19 PM)
After market: 0.7014 +0 (+0.2%)0.7
0 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners27.22%
Inst Owner Change-17.93%
Ins Owners34.79%
Ins Owner Change60.52%
Market Cap63.39M
Analysts78.33
Price Target9.44 (1248.57%)
Short Float %4.57%
Short Ratio2.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.16%
Min EPS beat(2)-30.9%
Max EPS beat(2)14.57%
EPS beat(4)2
Avg EPS beat(4)-5.87%
Min EPS beat(4)-30.9%
Max EPS beat(4)14.57%
EPS beat(8)4
Avg EPS beat(8)-3.84%
EPS beat(12)7
Avg EPS beat(12)12.4%
EPS beat(16)9
Avg EPS beat(16)13.93%
Revenue beat(2)1
Avg Revenue beat(2)-60.75%
Min Revenue beat(2)-137.73%
Max Revenue beat(2)16.23%
Revenue beat(4)3
Avg Revenue beat(4)6.77%
Min Revenue beat(4)-137.73%
Max Revenue beat(4)113.53%
Revenue beat(8)5
Avg Revenue beat(8)58.15%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-94.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-65.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.83
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.1
BVpS-0.38
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -258.12% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.08% | ||
| FCFM | N/A |
ROA(3y)-60.22%
ROA(5y)-55.89%
ROE(3y)-169.25%
ROE(5y)-136.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 27.07% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.22 | ||
| Altman-Z | -18.78 |
F-Score3
WACC11.45%
ROIC/WACCN/A
Cap/Depr(3y)166.38%
Cap/Depr(5y)1061.5%
Cap/Sales(3y)5.91%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
EPS Next Y-11.31%
EPS Next 2Y26.1%
EPS Next 3Y20.26%
EPS Next 5Y18.46%
Revenue 1Y (TTM)186.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-161.06%
Revenue Next Year95.42%
Revenue Next 2Y97.59%
Revenue Next 3Y112.21%
Revenue Next 5Y91.12%
EBIT growth 1Y-53.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.09%
EBIT Next 3Y21.13%
EBIT Next 5YN/A
FCF growth 1Y-160.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-165.04%
OCF growth 3YN/A
OCF growth 5YN/A